The observation that Braf is mutated in 40–60% of malignant melanomas and in tumours of the thyroid, colon and lung underscores the importance of the Ras-ERK pathway in malignant disease, making it an intense focus of anticancer drug discovery [122]. This evidence concerns the gene BRAF and melanoma.